SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ARMP

Armata Pharmaceuticals, Inc. (ARMP)

NYSE: ARMP · Real-Time Price · USD
Healthcare · Biotechnology
$2.99-$0.88 (-22.74%)
 
Market cap
$111M
Insider Score
Analyst consensus
Market Cap$111.21M-59.1%
Revenue (ttm)$7.55M
Net Income-$113.71M
EPS-$4.17
Shares Out37.19M
PE Ration/a
Forward PE-1.47
Dividendn/a
Ex-Dividend Daten/a
Volume159,496
Open$3.84
Previous Close$3.87
Day's Range$2.98 - $4.11
52-Week Range$2.75 - $14.98
Beta1.63
AnalystsStrong Buy
Price Target$17.50(+485.28%)
Earnings DateNov 12, 2026
-22.74% (1D)
No price history available.

About ARMP

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; and AP-PA03 for Pseudomonas aeruginosa. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.

Address
5005 McConnell Avenue, Los Angeles, CA, 90066, United States
Market Cap
111 million
Employees
61
Industrial Classification
Biotechnology
1 Day
-22.74%
5 Days
-21.32%
1 Month
-11.28%
6 Months
-60.66%
1 Year
-59.15%

$ARMP stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ARMP holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ARMP's directors and management

Net Shares Purchased by Insiders−1−102025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ARMP Estimated quarterly lobbying spending

Source: U.S. Senate LDA

ARMP Revenue by Segment

$6.44MTotal
Segment Reporting$3.27M50.77%
Grant and award revenue$3.17M49.23%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New ARMP patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ARMP from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from ARMP’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
62% of score
99
News & Sentiment
38% of score
78

News check: FDA Breakthrough Therapy designation for AP-SA02 is significant positive catalyst; data presentation and conference participation support development momentum.

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.14%

Weight is the stock’s share of each fund’s holdings.